Hangzhou Bio-Sincerity Pharma-TechLtd Future Growth
Future criteria checks 5/6
Hangzhou Bio-Sincerity Pharma-TechLtd is forecast to grow earnings and revenue by 29.8% and 26.6% per annum respectively. EPS is expected to grow by 29.6% per annum. Return on equity is forecast to be 15.8% in 3 years.
Key information
29.8%
Earnings growth rate
29.6%
EPS growth rate
Life Sciences earnings growth | 28.1% |
Revenue growth rate | 26.6% |
Future return on equity | 15.8% |
Analyst coverage | Low |
Last updated | 25 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,332 | 676 | N/A | 745 | 2 |
12/31/2025 | 1,749 | 518 | -141 | 614 | 5 |
12/31/2024 | 1,356 | 378 | -196 | 480 | 2 |
3/31/2024 | 1,072 | 287 | -751 | -28 | N/A |
12/31/2023 | 1,017 | 272 | -598 | 90 | N/A |
9/30/2023 | 900 | 250 | -520 | 135 | N/A |
6/30/2023 | 786 | 229 | -531 | 154 | N/A |
3/31/2023 | 673 | 210 | -388 | 289 | N/A |
12/31/2022 | 607 | 194 | -332 | 259 | N/A |
9/30/2022 | 573 | 192 | -319 | 241 | N/A |
6/30/2022 | 479 | 155 | -194 | 224 | N/A |
3/31/2022 | 425 | 126 | -178 | 117 | N/A |
12/31/2021 | 374 | 111 | -103 | 145 | N/A |
9/30/2021 | 304 | 101 | -167 | 100 | N/A |
6/30/2021 | 267 | 85 | -204 | 80 | N/A |
3/31/2021 | 211 | 55 | -229 | 49 | N/A |
12/31/2020 | 207 | 57 | -201 | 54 | N/A |
12/31/2019 | 156 | 44 | -35 | 71 | N/A |
12/31/2018 | 82 | 11 | 26 | 45 | N/A |
12/31/2017 | 26 | -7 | N/A | 11 | N/A |
6/30/2017 | 30 | 8 | N/A | 11 | N/A |
3/31/2017 | 27 | 5 | N/A | 6 | N/A |
12/31/2016 | 24 | 3 | N/A | 2 | N/A |
9/30/2016 | 21 | 1 | N/A | 1 | N/A |
6/30/2016 | 16 | -1 | N/A | 5 | N/A |
3/31/2016 | 16 | 2 | N/A | 4 | N/A |
1/1/2016 | 16 | 5 | N/A | 3 | N/A |
12/31/2014 | 6 | -2 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301096's forecast earnings growth (29.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 301096's earnings (29.8% per year) are forecast to grow faster than the CN market (24.2% per year).
High Growth Earnings: 301096's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301096's revenue (26.6% per year) is forecast to grow faster than the CN market (14.7% per year).
High Growth Revenue: 301096's revenue (26.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301096's Return on Equity is forecast to be low in 3 years time (15.8%).